Sinjard-L
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Empagliflozin & Linagliptin Hydrochloride is appropriate. And Empagliflozin reduces the risk of heart failure and chronic kidney disease.
Features
| Product Name | Sinjard-L |
| Generic Name | Empagliflozin + Linagliptin |
| Therapeutic Class | SGLT-2 inhibitor + DPP-4 inhibitor |
| Formulation | Tablet |
| Available Pack Size | 4 X 7’s & 2 X 7’s |
| Available Strength | Empagliflozin 10 mg + Linagliptin 5 mg & Empagliflozin 25 mg + Linagliptin 5 mg |